SFMN
Société Française de Médecine Nucléaire

SFMN
Société Française de Médecine Nucléaire
et Imagerie Moléculaire

SFMN
Société Française de Médecine Nucléaire
et Imagerie Moléculaire

SFMN
Société Française de Médecine Nucléaire
et Imagerie Moléculaire

La TEP à la 18F-FDOPA - VIII. REFERENCES

VIII. REFERENCES

 

Revues générales:

  1. PET tracers for imaging of the dopaminergic system. Elsinga PH, Hatano K, Ishiwata K.Curr Med Chem 2006;13:2139-53
  2. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization. Vallabhajosula S. Semin Nucl Med 2007;37:400-19

 

Tumeurs cérébrales:

  1. FDOPA PET has clinical utility in brain tumour imaging: a proposal for a revision of the recent EANM guidelines. Talbot JN, Kerrou K, Montravers F, Nataf V, Chevalme Y. Eur J Nucl Med Mol Imaging 2007;34:1131-2
  2. F-Dopa as an amino acid tracer to detect brain tumors. Heiss WD, Wienhard K, Wagner R, Lanfermann H, Thiel A, Herholz K et al. J Nucl Med 1996;37:1180-2
  3. Brain tumour imaging with PET: a comparison between [18F] fluorodopa and [11C] methionine. Becherer A, Karanikas G, Szabo M, Zettinig G, Asenbaum S, Marosi C et al. Eur J Nucl Med Mol Imaging 2003;30:1561-7
  4. 3-Omethyl- 6-[18F]fluoro-L-DOPA and its evaluation in brain tumour imaging. Beuthien-Baumann B, Bredow J, Burchert W, Fuchtner F, Bergmann R, Alheit HD et al. Eur J Nucl Med Mol Imaging 2003;30:1004-8
  5. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F FDG PET and evaluation of diagnostic accuracy. Chen W, Silverman DHS, Delaloye S, Czernin J, Kamdar N, Pope W, et al. J Nucl Med 2006;47:904–11
  6. EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues. Van der Borght T, Asenbaum S, Bartenstein P, Halldin C, Kapucu Ö, Van Laere K, et al. Eur J Nucl Med Mol Imaging 2006;33:1374–80
  7. PET and malignant cerebral tumors. Talbot JN, Kerrou K, Gault N, Gutman F, Grahek D, Touboul E, Schlienger M, Montravers F. Presse Med. 2006;35:1347-53
  8. 18F-FDOPA kinetics in brain tumors. Schiepers C, Chen W, Cloughesy T, Dahlbom M, Huang SC. J Nucl Med 2007;48:1651-61
  9. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. Chen W, Silverman DH, Delaloye S, Czernin J, Kamdar N, Pope W, Satyamurthy N, Schiepers C, Cloughesy T. J Nucl Med. 2006;47:904-11

 

Phéochromocytomes:

  1. Pheochromocytomas: detection with 18F DOPA whole body PET--initial results. Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I, Reincke M, Moser E, Neumann HP. Radiology 2002;222:507-12
  2. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas. Imani F, Agopian VG, Auerbach MS, Walter MA, Imani F, Benz MR, Dumont RA, Lai CK, Czernin JG, Yeh MW. J Nucl Med 2009;50:513-9
  3. The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas. Taïeb D, Tessonnier L, Sebag F, Niccoli-Sire P, Morange I, Colavolpe C, De Micco C, Barlier A, Palazzo FF, Henry JF, Mundler O. Clin Endocrinol 2008;69:580-6

 

Tumeurs endocrines:

  1. Update on nuclear medicine imaging of neuroendocrine tumors. Goldsmith SJ. Future Oncol 2009;5:75-84
  2. Imaging of neuroendocrine tumors. Rufini V, Calcagni ML, Baum RP. Semin Nucl Med 2006;36:228-47
  3. 6-L-18F-Fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. Jager P, Chirakal R, Marriott C, Brouwers A, Koopmans K, Gulenchyn K. J Nucl Med 2008;49:573-86.
  4. Impact of fluorodihydroxyphenylalanine-18F positron emission tomography on management of adult patients with documented or occult digestive endocrine tumors.
  5. Montravers F, Kerrou K, Nataf V, Huchet V, Lotz JP, Ruszniewski P, Rougier P, Duron F, Bouchard P, Grangé JD, Houry S, Talbot JN. J Clin Endocrinol Metab 2009;94:1295-301
  6. Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors? Montravers F, Grahek D, Kerrou K, Ruszniewski P, de Beco V, Aide N, Gutman F, Grangé JD, Lotz JP, Talbot JN. J Nucl Med 2006;47:1455-62
  7. Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. Becherer A, Szabó M, Karanikas G, Wunderbaldinger P, Angelberger P, Raderer M, Kurtaran A, Dudczak R, Kletter K. J Nucl Med 2004;45:1161-7
  8. The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Beheshti M, Pöcher S, Vali R, Waldenberger P, Broinger G, Nader M, Kohlfürst S, Pirich C, Dralle H, Langsteger W. Eur Radiol 2009;19:1425-34
  9. Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. Koopmans KP, de Vries EG, Kema IP, Elsinga PH, Neels OC, Sluiter WJ, van der Horst-Schrivers AN, Jager PL. Lancet Oncol 2006;7:728-34
  10. Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors. Hoegerle S, Altehoefer C, Ghanem N, Koehler G, Waller CF, Scheruebl H, Moser E, Nitzsche E. Radiology 2001;220:373-80

 

Hyperinsulinisme infantile:

  1. The added value of [18F]fluoro-L-DOPA PET in the diagnosis of hyperinsulinism of infancy: a retrospective study involving 49 children.
  2. Ribeiro MJ, Boddaert N, Bellanné-Chantelot C, Bourgeois S, Valayannopoulos V, Delzescaux T, Jaubert F, Nihoul-Fékété C, Brunelle F, De Lonlay P.
    Eur J Nucl Med Mol Imaging 2007;34:2120-8

 

Dosimétrie pédiatrique:

  1. The new EANM paediatric dosage card: additional notes with respect to F-18 Lassmann F, Biassoni L, Monsieurs M, Franzius C. EANM Dosimetry and Paediatrics Committees Eur J Nucl Med Mol Imaging 2008;35:1666–68

 

 

 

Compte utilisateur